Umbilical stem cells dubbed 'Holy Grail' for regenerative medicine
Umbilical stem cells from Wharton's Jelly offer non-invasive, scalable regenerative therapy options.
Why it matters
- Non-invasive and scalable stem cell source
- Potential for wide-ranging medical applications
By the numbers
- Cited study shows 31% decrease in ALS progression
The big picture
- Only one FDA-approved MSC therapy exists currently
- Could expand regenerative medicine if proven effective
What they're saying
- Expert skepticism due to past trial failures
- Patient hope for new treatment options
Caveats
- Review of existing studies, not new data
- Past MSC trials often failed in late stages
What’s next
- More trials to confirm benefits and safety
- Research on combining with biomaterials